Oncimmune Holdings plc (LON:ONC) has reacquired IP and distribution rights for its lung cancer diagnostic (EarlyCDT®) that has been recalibrated for enhanced accuracy in Asian populations. Trials are due to
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has successfully agreed to acquire the intellectual property and distribution rights for the EarlyCDT® technology in the People’s Republic of
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed two separate agreements with Roche Pharmaceuticals and Cedars-Sinai Medical Center, in each case to use
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its interim results for the six months ended 30 November 2020. Commercial highlights Services – ImmunoINSIGHTS · Marked increase in
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the publication by PLOS ONE of a study, supported by the Oncimmune’s ImmunoINSIGHTS team, which analysed autoantibodies in patients
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed a commercial contract to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney
Oncimmune Holdings plc (LON:ONC) has entered a commercial partnership with US West Coast biotech, Augmenta Bioworks, to profile patient plasma samples and characterise antibody therapeutic candidates discovered via Augmenta’s proprietary
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed a new master service agreement with Augmenta Bioworks, Inc. to profile patient plasma samples and
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has given notice that its Annual General Meeting will be held at 10:00 am on 30 November 2020 at the offices of
Oncimmune Holdings plc (LON:ONC) FY 2020 was the first full year of delivery under Oncimmune’s three-year plan of operational, technical and commercial targets for products and services, accomplishing major milestones
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
